Analysts think GTBP stock price could increase by 1111%
Dec 11, 2025, 12:25 PM
17.32%
What does GTBP do
GT Biopharma, a clinical-stage biopharmaceutical company based in Brisbane, California, focuses on immuno-oncology products using its TriKE NK cell engager platform, with its first candidate, GTB-3550, targeting cancer and HIV. Founded in 2013, the company employs two full-time staff and aims to enhance natural killer cell activity against diseases.
3 analysts think GTBP stock price will increase by 1111.22%. The current median analyst target is $8.16 compared to a current stock price of $0.67. The lowest analysts target is $8.08 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.